BR112014024358A2 - uso de iduronate-2-sulfatase por via subcutânea e kit - Google Patents

uso de iduronate-2-sulfatase por via subcutânea e kit

Info

Publication number
BR112014024358A2
BR112014024358A2 BR112014024358A BR112014024358A BR112014024358A2 BR 112014024358 A2 BR112014024358 A2 BR 112014024358A2 BR 112014024358 A BR112014024358 A BR 112014024358A BR 112014024358 A BR112014024358 A BR 112014024358A BR 112014024358 A2 BR112014024358 A2 BR 112014024358A2
Authority
BR
Brazil
Prior art keywords
iduronate
sulfatase
kit
present
provides
Prior art date
Application number
BR112014024358A
Other languages
English (en)
Other versions
BR112014024358A8 (pt
Inventor
Felice Brian
Xie Hongsheng
Mccauley Thomas
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of BR112014024358A2 publication Critical patent/BR112014024358A2/pt
Publication of BR112014024358A8 publication Critical patent/BR112014024358A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

administração subcutânea de iduronato-2-sulfatase resumo a presente invenção fornece, dentre outros, composições, kits e métodos para distribuição subcutânea de enzimas lisossomais para tratamento eficaz de doenças de depósito lisossômico. em algumas modalidades, a presente invenção fornece métodos para o tratamento da síndrome de hunter por via subcutânea de uma proteína de iduronate-2-sulfatase (i2s) de substituição. em algumas modalidades, a presente invenção fornece um kit composto por um arranjo de componentes para administrar a proteína de iduronato-2-sulfatase (i2s) por via subcutânea.
BR112014024358A 2012-03-30 2013-03-14 administração subcutânea de iduronato-2-sulfatase BR112014024358A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618638P 2012-03-30 2012-03-30
PCT/US2013/031662 WO2013148277A1 (en) 2012-03-30 2013-03-14 Subcutaneous administration of iduronate- 2-sulfatase

Publications (2)

Publication Number Publication Date
BR112014024358A2 true BR112014024358A2 (pt) 2017-12-05
BR112014024358A8 BR112014024358A8 (pt) 2018-01-23

Family

ID=49261057

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014024358A BR112014024358A8 (pt) 2012-03-30 2013-03-14 administração subcutânea de iduronato-2-sulfatase

Country Status (8)

Country Link
US (1) US9603908B2 (pt)
EP (1) EP2830642B1 (pt)
AU (1) AU2013240306A1 (pt)
BR (1) BR112014024358A8 (pt)
CA (1) CA2868466A1 (pt)
EA (1) EA201491578A1 (pt)
MX (1) MX2014011836A (pt)
WO (1) WO2013148277A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279522B1 (ko) 2012-11-02 2021-07-19 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
US20180125928A1 (en) * 2015-05-13 2018-05-10 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
KR20170004814A (ko) 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
DK3397270T3 (da) * 2015-12-30 2024-05-06 Green Cross Corp Sammensætninger til anvendelse i behandlingen af hunters syndrom
JP2021500857A (ja) 2017-10-02 2021-01-14 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 酵素補充療法用酵素を含む融合タンパク質
US11268079B2 (en) * 2018-08-01 2022-03-08 Integrated Micro-Chromatography Systems, Inc. Compositions of beta-glucuronidase enzyme blends with enhanced enzymatic activity and methods of preparation thereof
US11421210B2 (en) 2018-10-08 2022-08-23 Integrated Micro-Chromatography Systems, Inc. Chimeric and other variant beta-glucuronidase enzymes with enhanced properties

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
EP2325301B1 (en) 2003-02-11 2015-09-02 Shire Human Genetic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE)
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
WO2011041897A1 (en) * 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011163649A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc Methods and compositions for cns delivery of iduronate-2-sulfatase

Also Published As

Publication number Publication date
BR112014024358A8 (pt) 2018-01-23
EP2830642B1 (en) 2019-08-28
EP2830642A1 (en) 2015-02-04
MX2014011836A (es) 2015-03-09
CA2868466A1 (en) 2013-10-03
WO2013148277A1 (en) 2013-10-03
US9603908B2 (en) 2017-03-28
AU2013240306A1 (en) 2014-10-09
US20150086526A1 (en) 2015-03-26
EA201491578A1 (ru) 2015-04-30
EP2830642A4 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
BR112014024358A2 (pt) uso de iduronate-2-sulfatase por via subcutânea e kit
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
IN2014MN00333A (pt)
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
BR112014016557A8 (pt) métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais
BR112012033214A2 (pt) método e composições para distribuição no snc de iduronato-2-sulfatase
EA201170149A1 (ru) Новые аналоги инсулина пролонгированной активности
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112014007675A2 (pt) tratamento de doença articular degenerativa
GB2467670A (en) Chemical entities and therapeutic uses thereof
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
EP4124346A3 (en) Compositions and methods for treating diseases
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
BR112014009785A8 (pt) método para tratar ou reduzir efp
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
EA201491369A1 (ru) Способ лечения сахарного диабета при помощи негликозилированного аполипопротеина a-iv
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида
TR201901846T4 (tr) Aşı terapisi.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements